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Abstract 
Approximately 4,000 children in the United States are diagnosed each year with 
a brain tumor. Brain cancers are the deadliest of all pediatric cancers as they 
have survival rates of less than 20%. Typical treatments include surgery and 
radiation therapy. However, chemotherapy is the primary therapeutic option for 
children, especially against aggressive brain tumors. An important 
chemotherapeutic agent is temozolomide, an alkylating agent that causes cell 
death by damaging DNA. In this project, we tested the ability of non-natural 
nucleosides developed in our lab in order to increase the ability of temozolomide 
to kill brain cancer cells. Our results show that combining low doses of our 
nucleoside with temozolomide kills more cells compared to treatment with either 
compound individually. The increase in efficacy is specific for temozolomide as 
similar effects are not observed in cells treated with other chemotherapeutic 
agents such as cisplatin, 5-fluorouracil, and taxol. High-field microscopy 
techniques demonstrate that the combination of our nucleoside and 
temozolomide causes cell death via apoptosis as opposed to necrosis. A model 
is provided describing how our novel nucleoside analog increases the cell-killing 
effects of temozolomide by inhibiting the misreplication of damaged DNA 
created by this agent. Collectively, these studies provide pharmacological 
evidence for a new treatment strategy to more effectively treat patients with 
brain cancers.  
 
  
